Details

Autor(en) / Beteiligte

• Maisonneuve, Patrick
• Agodoa, Lawrence
• Gellert, Ryszard
• Stewart, John H
• Buccianti, Gheardo
• Lowenfels, Albert B
• Wolf, Robert A
• Jones, Elisabeth
• Dsiney, Alex PS
• Briggs, Douglas
• McCredie, Margaret
• Boyle, Peter

Titel

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

Ist Teil von

• The Lancet (British edition), 1999-07, Vol.354 (9173), p.93-99

Ort / Verlag

London: Elsevier Ltd

Erscheinungsjahr

1999

Quelle

Business Source Ultimate【Trial: -2024/12/31】【Remote access available】

Beschreibungen/Notizen

• Previous studies have suggested that the frequency of cancer is higher in patients with end-stage renal disease (ESRD) than in the general population, but have not established whether this increase is confined to certain cancers or to certain categories of ESRD patients. The aim of this study was to examine the risk of cancer in a large cohort of patients treated by dialysis but not transplantatih We assembled a cohort of 831804 patients who received dialysis during the period 1980–94 for ESRD in the USA, Europe, Australia, or New Zealand. We compared the observed frequency cancer among these patients during 2045035 person-years of follow-up with the frequency of cancer in the respective background populations. During average follow-up of 2–5 years, 25 044 (3%) of 831804 patients developed cancer compared with an expected number of 21 185 (standardised incidence ratio 1–18 [95% Cl 1-17-1. 20]). We observed a higher risk of cancer in patients younger than 35 years (3-68 [–39-3-99]), and the risk gradually decreased with increasing age. High risks were observed for cancer of the kidney (3-60 [3-45-3-76]), bladder (1-50][1-42-1-57]), and thyroid and other endocrine organs (2-28 [2-[2-3-54]). Excess cancers appeared in several organs for which viruses have been suspected as causative agents, whereas cancers of the lung, colorectum, prostate, breast, and stomach were not consistently increased The overall risk of cancer is increased in patients with ESRD, and the distribution of tumour types resembles the pattern seen after transplantation (although we have no data to make the comparison with skin cancer). The excess risk can largely be ascribed to effects of underlying renal or urinary-tract disease, or of loss of renal function, on the kidney and bladder, and to increased susceptibility to viral carcinogenesis. The relative risk, which is especially high in younger patients, gradually diminishes with age